Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Troponin T, slow skeletal muscle (TNNT1) is a subunit of the troponin complex specifically expressed in the sarcomeres of slow-twitch skeletal muscle fibers[1][3]. It plays a crucial structural and regulatory role by anchoring the troponin complex to tropomyosin and the actin filament, thereby enabling calcium-regulated muscle contraction. Mutations in the TNNT1 gene disrupt the assembly or function of the troponin complex, abolishing proper muscle contraction, and cause severe, recessively inherited nemaline myopathy—most notably Amish nemaline myopathy (ANM)—which manifests as profound muscle weakness, atrophy of type I muscle fibers, and is often fatal in early infancy. TNNT1 is not considered a typical therapeutic target like receptors or enzymes, but its essential role in muscle physiology makes it a critical protein in skeletal muscle biology[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Troponin T, slow skeletal muscle (TNNT1).